Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PULMO-01: roginolisib with dostarlimab with or without docetaxel in advanced non-squamous NSCLC
2024-517741-14-00Phase 2Authorised
- Sponsor
- iOnctura
- Start
- Apr 2025
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label trial of roginolisib, dostarlimab and docetaxel in Non-small cell lung cancer (NS-NSCLC) (2 arms), sponsored by iOnctura. Primary endpoint: CyTOF response by Day 42. Planned start Apr 2025; status: authorised.
02
Drugs
roginolisibdostarlimabdocetaxel
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on 2024-517741-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517741-14-00.